Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest BVCF Stories

2013-08-22 04:21:55

-- Funds U.S. Development of MRX-I Next-Generation Antibiotic -- HAYWARD, Calif. and SHANGHAI, Aug. 22, 2013 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures. Proceeds...